There are currently 79 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Autism participants are California, Ohio, Illinois and Michigan.
Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia
NCT05677919
Recruiting
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the body after cancer treatment called minimal residual disease as a guide to determine length of treatment. Drugs used in chemotherapy, such as pirtobrutinib and venetoclax, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
NCT02846623
Recruiting
This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Register for Updates
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
NCT04560322
Recruiting
This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: obinutuzumab venetoclax acalabrutinib
Gender:
All
Ages:
18 years and above
Trial Updated:
07/05/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
A Study Of The Selective PKC-β Inhibitor MS- 553
NCT03492125
Recruiting
A Phase I/II Dose-Escalation and Expansion Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2023
Locations: University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan +4 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
Register for Updates
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
NCT04155710
Recruiting
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2023
Locations: Moffitt Cancer Center, Tampa, Florida +6 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/03/2022
Locations: Goshen Center for Cancer Care, Goshen, Indiana +44 locations
Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Register for Updates
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT05211856
Recruiting
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
01/14/2022
Locations: Research Site, Fountain Valley, California +277 locations
Conditions: Chronic Lymphocytic Leukemia
Register for Updates